Amendment to Research Subaward Agreement, entered into as of August 11, 2020, by and between Registrant and Yale University
EX-10.1 2 mgen-q32020xex101yale.htm EX-10.1 Document
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN REDACTED BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK, “[*]”.
Pass-Through Entity (PTE)
Miragen Therapeutics, Inc.
Rusty Montgomery, MD
Mir-29 mimicry as a therapy for pulmonary fibrosis
PTE Federal Award No:
Federal Awarding Agency:
National Institutes of Health (NIH)
Revised Period of Performance:
Amount Funded This Action:
|September 1, 2018|
|Jun 30, 2021|
Total Amount of Federal Funds Obligated to Date:
|Cost Share:||Subject to FFATA:|
Amendment(s) to Original Terms and Conditions
This Amendment revises the above-referenced Subaward Agreement as follows:
|ü||This is a [*] Extension. The Period of Performance is hereby extended through:||06/30/2021|
|to||is hereby added to the Period of Performance, which is revised to be consistent with the Period of Performance Start and End Date above.|
|Additional funds in the amount of||are hereby authorized for the current period.|
|Carryover in the amount of||is hereby authorized as shown below.|
|Other (see below)|
For clarity: all amounts stated in this amendment are in United States Dollars.
All other terms and conditions of this Subaward Agreement remain in full force and effect.
By an Authorized Official of PTE:
By an Authorized Official of Subrecipient:
/s/ Lindsey Bosak
Aug 20, 2020
/s/ Jason A. Leverone
Aug 11, 2020
Jason A. Leverone
Award Manager, SO/AOR